Vision booster? citicoline tested after glaucoma surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \> 18 years * Ability to understand the protocol and provide informed consent to participate in the study * Diagnosis of primary or secondary open-angle glaucoma (PEX - PIG) and the need to undergo subconjunctival filtration surgery due to signs of morphological/functional progression of the condition or failure to achieve target pressure with medical or pre-surgical therapy. The diagnosis of glaucoma is defined by the presence of typical ophthalmoscopic damage to the optic nerve head and the consequent visual field defect. In particular, a glaucomatous visual field defect will be considered as such if there is a cluster of 3 or more contiguous points in the pattern deviation plot with a probability of occurrence in the normal population of less than 5%, one of which has a probability of less than 1%, a pattern standard deviation with a probability of less than 5%, or a GHT result outside the normal limits. * Early to moderate visual field defect, according to the Hodapp-Parrish-Anderson classification, i.e. with MD up to -12 dB, as determined by the Humphrey 24-2 SITA Standard computerised test. * Rate of visual field defect progression \> 0.5 dB/year, in the 2 years prior to surgery. * At least 3 visual field examinations performed using standard perimetry in the 2 years prior to surgery. Exclusion Criteria: * Diagnosis of angle-closure glaucoma * Previous glaucoma surgery (trabeculectomy, valve implantation or placement of other devices, cyclophotocoagulation) * Previous vitreoretinal or corneal eye surgery * Visual, neurological or general medical conditions that may affect the visual field, electrophysiological tests, OCT or A-OCT scans * Systemic administration (oral or parenteral) of cerebral vasoactive drugs, neurotrophic agents, lutein, zeaxanthin, docosahexaenoic acid, ubiquinone and/or its derivatives, citicoline and/or its derivatives within 6 months prior to enrolment in the study * Topical therapy with citicoline and/or its derivatives within 6 months prior to enrolment in the study * Known or suspected allergy or sensitisation to the study product * Pregnancy or breastfeeding